Although limited to 21 cases, individuals classified within DP9 stood out from the other subgroups owing to their very adverse outcomes, indicating the need for a distinct therapeutic strategy for MDS with NPM1 [20,21]. This evidence concerns the gene NPM1 and myelodysplastic syndrome.